Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department
Authors:
- Jesse MartinezJMJesse Martinez
- Nipam Mbbs ShahNSNipam Mbbs Shah
- Will KenanWKWill Kenan
- Andrew FowlerAFAndrew Fowler
- Nita PharmD LimdiNLNita PharmD Limdi
- Lindsey Mba BurnsLBLindsey Mba Burns
- Elizabeth S. CoganECElizabeth S. Cogan
- Anna GardinerAGAnna Gardiner
- Daniel Bs HainDHDaniel Bs Hain
- Holly JohnsonHJHolly Johnson
- David LewisDLDavid Lewis
Open Access
- 22 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Pediatric Emergency Care
- Vol. 39 (1) , 6-12
Abstract
Objective: The aim of the study was to evaluate the ability of a combinatorial pharmacogenomic test to predict medication blood levels and relative clinical improvements in a selected pediatric population. Methods: This study enrolled patients between ages 3 to 18 years who presented to a pediatric emergency department with acute psychiatric, behavioral, or mental health crisis and/or concerns, and had previously been prescribed psychotropic medications. Patients received combinatorial pharmacogenomic testing with medications categorized according to gene-drug interactions (GDIs); medications with a GDI were considered “incongruent,” and medications without a GDI were considered “congruent.” Blood levels for escitalopram, fluoxetine, aripiprazole, and clonidine were evaluated according to level of GDI. Relative clinical improvements in response to the prescribed psychotropic medications were measured using a parent-rated Clinical Global Impression of Improvement (CGI-I) assessment, where lower scores corresponded with greater improvement. Results: Of the 100 patients enrolled, 73% reported taking ≥1 incongruent medication. There was no significant difference in CGI-I scores between patients prescribed congruent versus incongruent medications (3.37 vs 3.68, P = 0.343). Among patients who presented for depression or suicidal ideation, those prescribed congruent medications had significantly lower CGI-I scores compared with those taking incongruent medications (P = 0.036 for depression, P = 0.018 for suicidal ideation). There was a significant association between medication GDI and blood levels for aripiprazole (n = 15, P = 0.01) and escitalopram (n = 10, P = 0.01). Conclusions: Our preliminary findings suggest that combinatorial pharmacogenomic testing can predict medication blood levels and relative outcomes based on medication congruency in children presenting to an emergency department with acute psychiatric/behavioral crises. Additional studies will be needed to confirm these findings.Keywords
This publication has 24 references indexed in Scilit:
- Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough?Current Problems in Pediatric and Adolescent Health Care, 2018
- Antidepressant Prescribing by Pediatricians: A Mixed-Methods AnalysisCurrent Problems in Pediatric and Adolescent Health Care, 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical Pharmacology & Therapeutics, 2015
- A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.2013
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- Treatment of Pediatric Bipolar Disorder: A Review2011
- Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP projectThe Pharmacogenomics Journal, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Remission versus response as the goal of therapy in ADHD: A new standard for the field?Clinical Therapeutics, 2006